A vaccine for genital herpes using a radically different scientific approach
The Simplexia vaccine approach is based upon the observation that HSV-1 infection, oral herpes, acquired during childhood does not provide protection against later HSV-2 (genital herpes) infection. Consequently our HSV-2 vaccine candidate contains a protein, glycoprotein G-2, that is unique for HSV-2.
“By focusing on the G-2 (gG-2) protein our approach has used the experiences from earlier research. Yet, it is a completely new approach for treating and preventing genital herpes.”
Tim Wood
CEO Simplexia AB
The unmet clinical need
A Silent Epidemic
Many people with genital herpes aren't even aware that they're infected with the virus and may not find out they are infected until they pass it on to a subsequent partner who develops symptoms.